ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m ...
London, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added ...
PARIS, April 10, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed the acquisition of Nucleis, a specialist in GMP manufacturing and ...
Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) ...
Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, ...
The MarketWatch News Department was not involved in the creation of this content. -- A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic ...
Primary staging of patients with high-risk PCa prior to initial curative therapy To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific ...
Curium will shortly open a new facility to manufacture cutting-edge diagnosis technology for diseases like cancer at the Churchill Hospital site, part of Oxford University Hospitals NHS Foundation ...
The acquisition of Nucleis will: Enhance Curium's PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results